Literature DB >> 17692456

High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

María Moreno1, Hetty J Bontkes, Rik J Scheper, Peter Kenemans, René H M Verheijen, Silvia von Mensdorff-Pouilly.   

Abstract

The huHMFG-1 (AS1402) antibody is a humanised IgG1 directed against MUC1 and is currently in clinical trials for the treatment of breast carcinoma. Adenocarcinomas over-express and shed MUC1, and high MUC1 serum levels are associated with progressive disease. Here, we have investigated the effects of MUC1 present in sera from breast and ovarian cancer patients and that of NK cells on in vitro huHMFG-1-mediated ADCC, performed with and without the addition of various cytokines. Screening for patients with high levels of NK cells bearing the FcgammaRIIIa-158V polymorphism, adjusting the dosage to circulating levels of MUC1 and co-administration of NK cell activating cytokines may increase the efficacy of huHMFG-1 treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17692456     DOI： 10.1016/j.canlet.2007.06.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  12 in total

1.  Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.

Authors:  John Gordon Bruno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02       Impact factor: 2.416

2.  Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.

Authors:  Kirstine Lavrsen; Caroline B Madsen; Morten G Rasch; Anders Woetmann; Niels Ødum; Ulla Mandel; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  Glycoconj J       Date:  2012-08-10       Impact factor: 2.916

3.  Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

Authors:  Govind Panchamoorthy; Caining Jin; Deepak Raina; Ajit Bharti; Masaaki Yamamoto; Dennis Adeebge; Qing Zhao; Roderick Bronson; Shirley Jiang; Linjing Li; Yozo Suzuki; Ashujit Tagde; P Peter Ghoroghchian; Kwok-Kin Wong; Surender Kharbanda; Donald Kufe
Journal:  JCI Insight       Date:  2018-06-21

Review 4.  Recent advances on applications of immunosensing systems based on nanomaterials for CA15-3 breast cancer biomarker detection.

Authors:  Ika Kustiyah Oktaviyanti; Diyar Salahuddin Ali; Sura A Awadh; Maria Jade Catalan Opulencia; Shukhrat Yusupov; Rui Dias; Fahad Alsaikhan; Mais Mahmood Mohammed; Himanshu Sharma; Yasser Fakri Mustafa; Marwan Mahmood Saleh
Journal:  Anal Bioanal Chem       Date:  2022-05-31       Impact factor: 4.142

5.  TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution.

Authors:  Forrest G FitzGerald; Maria C Rodriguez Benavente; Camelia Garcia; Yaima Rivero; YashoNandini Singh; Hongjie Wang; Gregg B Fields; Maré Cudic
Journal:  Glycoconj J       Date:  2020-10-01       Impact factor: 2.916

6.  Endogenous antibody responses to mucin 1 in a large multiethnic cohort of patients with breast cancer and healthy controls: Role of immunoglobulin and Fcγ receptor genes.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Bethany Wolf; Motoki Iwasaki; Yoshio Kasuga; Gerson S Hamada; Shoichiro Tsugane
Journal:  Immunobiology       Date:  2017-10-18       Impact factor: 3.144

7.  Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

Authors:  Li Wang; Hongmin Chen; Mohammad H Pourgholami; Julia Beretov; Jingli Hao; Hongtu Chao; Alan C Perkins; John H Kearsley; Yong Li
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

8.  Molecular basis of antibody binding to mucin glycopeptides in lung cancer.

Authors:  Jin Qu; Hongtao Yu; Fenge Li; Chunlei Zhang; Ahmad Trad; Cory Brooks; Bin Zhang; Ting Gong; Zhi Guo; Yunsen Li; Govind Ragupathi; Yanyan Lou; Patrick Hwu; Wei Huang; Dapeng Zhou
Journal:  Int J Oncol       Date:  2015-12-18       Impact factor: 5.650

9.  Natural and Induced Humoral Responses to MUC1.

Authors:  Silvia Von Mensdorff-Pouilly; Maria Moreno; René H M Verheijen
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

10.  Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.

Authors:  Janardan P Pandey; Aryan M Namboodiri
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.